Device’s list price has doubled since incentive plan was adopted in 2014

The drugmaker at the center of a firestorm over hefty price increases on the lifesaving EpiPen put a special incentive plan in place more than two years ago that rewards executives if they hit aggressive profit targets.

In early 2014, the board of Mylan NV approved a one-time award for more than 100 employees that hinged on more than doubling the company’s adjusted per-share earnings over a five-year period ending in 2018, Mylan’s regulatory filings show. Meeting that goal would require 16% compound annual earnings...

RELATED VIDEO

Mylan: Generic, Cheaper Version of EpiPen on the Way

Mylan announced a cheaper, generic version of EpiPen, its lifesaving product used by people with serious allergic reactions. WSJ's Austen Hufford explains on Lunch Break with Tanya Rivero. Photo: AP